In addition, Dr. John Beadle has been nominated as a new Board member. Susanne Stuffers will continue as a Board member.

“On behalf of the management team, I am very pleased to welcome Barbara as the incoming Chair of Nykode subject to election at the EGM. Her breadth of experience across strategic partnering, drug development and global biotech leadership will provide invaluable guidance as we progress our programs and position the company for its next phase of growth. I would also like to welcome John to the Board. His deep understanding of immunotherapy technologies, translational oncology, and advanced therapeutic development will be a tremendous asset to Nykode,” says Michael Engsig, Chief Executive Officer of Nykode.

Barbara Krebs-Pohl

Krebs-Pohl is a seasoned biotech executive with more than 25 years of global experience across R&D, business development, licensing, alliance management, portfolio management, and strategic transformation. Her career includes a distinguished 20-year tenure at MorphoSys AG, where she held roles including Chief Business Officer, Chief Integration Officer and Senior Vice President of Global Business Development & Licensing and Alliance Management. She played a central role in multiple high-value transactions, strategic partnerships, and the company’s evolution leading up to its eventual acquisition by Novartis.

“I am honored to be nominated as Chair of the Board of Nykode. The company’s unique technology platform, its scientific excellence, and its commitment to developing transformational immunotherapies strongly resonate with my experience and values. I look forward to working closely with the Board and management team to support Nykode’s continued growth, further internationalization, and the advancement of its promising pipeline,” says Barbara Krebs-Pohl.

She currently serves as independent director of CASI Pharmaceuticals (Nasdaq), Chair of the Board of OneChain Immunotherapeutics (Spain), Managing Director of the Foundation of Stem Cell Therapy and Regenerative Medicine and Managing Director of Viopas Venture Consulting (Germany). Her scientific background includes a PhD focused on antibody technologies, combined with extensive early-career work in immunology, oncology and discovery research.

John Beadle

Beadle is an experienced biotechnology entrepreneur, physician, and senior executive with more than 25 years of global leadership across immunotherapy development, gene therapy, and oncology. He is best known as the founding CEO of PsiOxus Therapeutics, where he advanced multiple clinical programs, secured major strategic partnerships, raised substantial capital, and built an IPO-ready organization. He currently serves as Non-Executive Chair of Vitarka Therapeutics and Non-Executive Director of Pneumagen, CamGene Therapeutics and Icosphere Biosciences. Earlier in his career, he co-founded PowderMed and contributed to the first clinical efficacy signal for a nucleotide-based vaccine, later supporting the company’s sale to Pfizer. He also held senior roles in R&D, product development, and global medical operations at GSK, Pfizer, PowderJect Pharmaceuticals, and Glaxo Wellcome.

“Nykode’s modular immunotherapy platforms are among the most innovative in the field, with clear potential to transform how we approach immune-mediated disease and cancer. I am delighted to be nominated to the Board and contribute my experience in translational development, advanced therapy platforms, and company building as Nykode continues to advance its strategy and clinical programs,” says John Beadle.